Literature DB >> 28531809

Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: A review.

Gorm Pihl-Jensen1, Mathias Falck Schmidt2, Jette Lautrup Frederiksen3.   

Abstract

Multifocal visual evoked potential (mf-VEP) represents a new approach to the classical full field (ff-)VEP with separate responses from up to 60 sectors of the visual field. A thorough literature survey of the use of mf-VEP in optic neuritis (ON) and multiple sclerosis (MS) is presented (38 published studies were retrieved). Mf-VEP provides direct topographical information of specific lesions and facilitates investigations on structural-functional correlations thus providing new methods for exploring the interplay between demyelination, atrophy and remyelination in MS. Good correlation was shown between mf-VEP and OCT, ff-VEP, MRI (MTR, DTI), 30-2 standard automated perimetry and low-contrast-visual acuity. All but one study showed superior sensitivity and specificity compared to ff-VEP, especially with regards to small, peripheral lesions or lesions of the upper visual field. Mf-VEP has shown superior sensitivity and specificity than established methods in diagnosing optic nerve lesions and tracking functional recovery following lesions. Abnormal mf-VEP responses in the fellow, non-ON afflicted eye may predict MS risk in ON patients. No standardization currently exists and no direct comparisons in ON and MS between at least 5 different commercially available mf-VEP systems have so far been published. Despite these limitations, mf-VEP is a promising new tool of diagnostic and prognostic value of mf-VEP in ON and MS.
Copyright © 2017 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical neurophysiology; Multifocal visual evoked potentials; Multiple sclerosis; Optic neuritis

Mesh:

Year:  2017        PMID: 28531809     DOI: 10.1016/j.clinph.2017.03.047

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  10 in total

1.  Evoked potentials as a biomarker of remyelination.

Authors:  Moones Heidari; Abigail B Radcliff; Gillian J McLellan; James N Ver Hoeve; Kore Chan; Julie A Kiland; Nicholas S Keuler; Benjamin K August; Dylan Sebo; Aaron S Field; Ian D Duncan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

2.  Multifocal visual evoked potentials and contrast sensitivity correlate with ganglion cell-inner plexiform layer thickness in multiple sclerosis.

Authors:  Divya Narayanan; Han Cheng; Rosa A Tang; Laura J Frishman
Journal:  Clin Neurophysiol       Date:  2018-11-13       Impact factor: 3.708

3.  Involvement of High Mobility Group Box 1 Protein in Optic Nerve Damage in Diabetes.

Authors:  Ghulam Mohammad; Renu A Kowluru
Journal:  Eye Brain       Date:  2022-05-10

4.  Functional-structural assessment of the optic pathways in patients with optic neuritis.

Authors:  Mathias Falck Schmidt; Gorm Pihl-Jensen; Jette Lautrup Frederiksen
Journal:  Doc Ophthalmol       Date:  2019-10-17       Impact factor: 2.379

5.  Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.

Authors:  Alexander Klistorner; Yi Chai; Letizia Leocani; Philipp Albrecht; Orhan Aktas; Helmut Butzkueven; Tjalf Ziemssen; Focke Ziemssen; Jette Frederiksen; Lei Xu; Diego Cadavid
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

6.  A computer-aided diagnosis of multiple sclerosis based on mfVEP recordings.

Authors:  Luis de Santiago; E M Sánchez Morla; Miguel Ortiz; Elena López; Carlos Amo Usanos; M C Alonso-Rodríguez; R Barea; Carlo Cavaliere-Ballesta; Alfredo Fernández; Luciano Boquete
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

7.  Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial.

Authors:  Christian Albert; Janine Mikolajczak; Anja Liekfeld; Sophie K Piper; Michael Scheel; Hanna G Zimmermann; Claus Nowak; Jan Dörr; Judith Bellmann-Strobl; Claudia Chien; Alexander U Brandt; Friedemann Paul; Olaf Hoffmann
Journal:  BMC Neurol       Date:  2020-03-03       Impact factor: 2.474

8.  Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis.

Authors:  Steffen Pfeuffer; Laura Kerschke; Tobias Ruck; Leoni Rolfes; Marc Pawlitzki; Philipp Albrecht; Heinz Wiendl; Sven G Meuth
Journal:  Ther Adv Neurol Disord       Date:  2021-03-06       Impact factor: 6.570

Review 9.  Optic Neuritis in Multiple Sclerosis-A Review of Molecular Mechanisms Involved in the Degenerative Process.

Authors:  Manuela Andreea Ciapă; Delia Lidia Șalaru; Cristian Stătescu; Radu Andy Sascău; Camelia Margareta Bogdănici
Journal:  Curr Issues Mol Biol       Date:  2022-09-02       Impact factor: 2.976

Review 10.  Clinical electrophysiology of the optic nerve and retinal ganglion cells.

Authors:  Oliver R Marmoy; Suresh Viswanathan
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 3.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.